Literature DB >> 9828782

Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM.

S Mäkimattila1, P Summanen, I Matinlauri, M Mäntysaari, A Schlenzka, M Aalto, K Irjala, H Yki-Järvinen.   

Abstract

BACKGROUND/AIMS: Recent studies have demonstrated marked renin and prorenin concentration gradients between ocular tissues and blood, and local expression of the renin-angiotensin system (RAS) in the eye. The authors determined whether serum total renin, which mostly consists of prorenin, is a marker of the activity and severity of diabetic retinopathy independent of other microvascular complications.
METHODS: Total renin concentrations (TRC) were measured with a time resolved immunofluorometric assay in 38 patients with IDDM (age 34 (SD 7) years, duration of disease 22 (7) years, serum creatinine 95 (15) mumol/l, urinary albumin excretion rate (UAER) 207 (829) micrograms/min, HbA1c 8.5% (1.2%)), and in 13 matched normal subjects. All subjects were carefully characterised with respect to the presence and severity of retinopathy (RP score), nephropathy, and neuropathy using seven different tests of autonomic neuropathy.
RESULTS: Serum TRC was on average twofold higher in IDDM (396 (SE 211) ng/l) than in normal subjects (201 (88) ng/l, p < 0.001). It was nearly twofold higher in patients with preproliferative or active proliferative retinopathy requiring careful follow up or therapy (TRC 596 (268) ng/l, n = 11) compared with those with quiescent proliferative retinopathy after laser treatment (TRC 338 (183) ng/l, p < 0.01, n = 5); moderately severe non-proliferative retinopathy (337 (106) ng/l, p < 0.01, n = 13), no retinopathy, or only minimal non-proliferative retinopathy (270 (43) ng/l, p < 0.001, n = 9). In multiple linear regression analysis, RP score (p < 0.01), but not the UAER or any index of autonomic neuropathy, was an independent determinant of serum TRC, and explained 32% of its variation (R = 0.57, p < 0.005).
CONCLUSIONS: Serum TRC in patients with diabetic retinopathy is increased independent of renal function and autonomic neuropathy especially in those with severe active changes requiring careful follow up or treatment. These findings support the idea that diabetic retinopathy is the most important determinant of serum TRC in patients with IDDM, and that TRC is produced when retinopathy is active.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828782      PMCID: PMC1722724          DOI: 10.1136/bjo.82.8.939

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  30 in total

1.  Plasma prorenin and renin in anephric patients.

Authors:  J E Sealey; R P White; J H Laragh; A L Rubin
Journal:  Circ Res       Date:  1977-10       Impact factor: 17.367

2.  Neovascularization produced by angiotensin II.

Authors:  L A Fernandez; J Twickler; A Mead
Journal:  J Lab Clin Med       Date:  1985-02

3.  Elevated serum total renin is insensitive in detecting incipient diabetic nephropathy.

Authors:  I H Matinlauri; T Rönnemaa; P J Koskinen; M A Aalto; J S Vukari; K M Irjala
Journal:  Diabetes Care       Date:  1995-10       Impact factor: 19.112

4.  Assessment of autonomic function in humans by heart rate spectral analysis.

Authors:  B Pomeranz; R J Macaulay; M A Caudill; I Kutz; D Adam; D Gordon; K M Kilborn; A C Barger; D C Shannon; R J Cohen
Journal:  Am J Physiol       Date:  1985-01

Review 5.  Prorenin and other large molecular weight forms of renin.

Authors:  J E Sealey; S A Atlas; J H Laragh
Journal:  Endocr Rev       Date:  1980       Impact factor: 19.871

6.  Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system.

Authors:  J Wagner; A H Jan Danser; F H Derkx; T V de Jong; M Paul; J J Mullins; M A Schalekamp; D Ganten
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

7.  A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography.

Authors:  R A Cole; J S Soeldner; P J Dunn; H F Bunn
Journal:  Metabolism       Date:  1978-03       Impact factor: 8.694

8.  Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study.

Authors:  S J Aldington; E M Kohner; S Meuer; R Klein; A K Sjølie
Journal:  Diabetologia       Date:  1995-04       Impact factor: 10.122

9.  Renin-containing Müller cells of the retina display endocrine features.

Authors:  J L Berka; A J Stubbs; D Z Wang; R DiNicolantonio; D Alcorn; D J Campbell; S L Skinner
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-06       Impact factor: 4.799

10.  Recuperative potential of cardiac muscle following relief of pressure overload hypertrophy and right ventricular failure in the cat.

Authors:  R L Coulson; S Yazdanfar; E Rubio; A A Bove; G M Lemole; J F Spann
Journal:  Circ Res       Date:  1977-01       Impact factor: 17.367

View more
  4 in total

1.  Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay.

Authors:  H Yokota; F Mori; K Kai; T Nagaoka; N Izumi; A Takahashi; T Hikichi; A Yoshida; F Suzuki; Y Ishida
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 2.  Protection from vascular risk in diabetic hypertension.

Authors:  D B Corry; M L Tuck
Journal:  Curr Hypertens Rep       Date:  2000-04       Impact factor: 5.369

3.  Receptor-mediated nonproteolytic activation of prorenin and induction of TGF-β1 and PAI-1 expression in renal mesangial cells.

Authors:  Jiandong Zhang; Jie Wu; Chunyan Gu; Nancy A Noble; Wayne A Border; Yufeng Huang
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-25

4.  Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.

Authors:  Jiandong Zhang; Nancy A Noble; Wayne A Border; Rick T Owens; Yufeng Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 5.900

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.